VOLUME 10, NUMBER 2, MARCH-APRIL 2024
Editorial by Céline Masson and Caroline Eliacheff in Unicancer's scientific journal, published in partnership with AERIO and SFjRO and partner journal of the IFODS congress, Innovations & Thérapeutiques en Oncologie.
❝ For over ten years, an influential movement for the rights of trans people, involving activists, doctors, the media, celebrities and influencers, has been imposing its standards of care on young people who declare that they want to ‘change sex’. According to them, professionals must ‘accompany’ minors during their transition, but without questioning their request: in the name of the child's self-determination, the self-diagnosis (‘I am trans’) is tantamount to a diagnosis of ‘gender dysphoria’. Anyone who disagrees with this principle is accused of transphobia... ❞
Innovations & Thérapeutiques en Oncologie, Unicancer's scientific journal, published in partnership with AERIO and SFjRO and partner journal of the IFODS congress, has three main missions:
To bring innovations in oncology to the attention of as many people as possible, trying as accurately as possible to define their interests, constraints and limitations;
To report on the day-to-day impact of these innovations in clinical practice;
Encourage new ways of using them and suggest new approaches based on specific clinical situations.
With its editorial board made up of leading professionals who are experts in their respective fields, Innovations & Thérapeutiques en Oncologie offers excellent content that will contribute, in its own way, to the oncology of tomorrow.
Innovations & Thérapeutiques en Oncologie focuses on innovative aspects of care, and boasts a forward-looking editorial line. This unique approach means that Innovations & Thérapeutiques en Oncologie is perfectly attuned to the increasingly rapid changes taking place in the world of oncology.
Comments